Navigation Links
Focal Cryoablation Highlighted in Urology Times Best of AUA Orlando 2008
Date:7/30/2008

Publication Highlights the Treatment's 'Low Rates of Morbidity'

IRVINE, Calif., July 30 /PRNewswire-FirstCall/ -- Endocare, Inc. (Nasdaq: ENDO), an innovative medical device company focused on the development of minimally invasive technologies used by urologists and interventional radiologists for tissue and tumor ablation, announced today that focal cryoablation was highlighted as having "low morbidity" in the July issue of Urology Times. Focal cryoablation is a minimally-invasive method of freezing and destroying only the cancerous portion of the prostate gland while leaving the healthy tissue and the nerves intact, resulting in low overall morbidity and a high rate of sexual potency. Focal cryoablation represents an important new option for prostate cancer patients who have isolated, localized disease.

Noting the data presented at the annual meeting of the American Urological Association (AUA) in Orlando, the July issue of Urology Times captured and summarized key take-home messages in 27 topic areas including "localized prostate cancer." The publication highlighted "low rates of morbidity" that result from focal cryoablation.

Focal cryoablation outcomes reported on at the AUA's annual meeting included the first multi-center study of focal, or partial gland, cryoablation for 341 prostate cancer patients. The study demonstrated that more than half of the patients who were potent before the treatment were again potent after six months, and more than 74 percent resumed potency within 36 months. Patients in this study are part of the Cryo On-Line Database (COLD) Registry which contains records for more than 5,000 cryoablation procedures from 48 physicians. This latest focal cryoablation study, the largest published thus far, reported similar outcomes to earlier studies, some of which have followed patients for up to 10 years with excellent long-term cancer control rates.

"Physicians and patients have struggled to find a middle ground between under-treating prostate cancer, by 'watchful waiting,' and over-treating through radical prostatectomy," said Endocare Chairman, CEO and President Craig T. Davenport. "There is a growing body of evidence that focal cryoablation may be an effective option for men who want to consider destroying localized focal cancer while at the same time preserving their quality of life."

Also at the conference this year, the AUA for the first time ever adopted an official set of clinical guidelines, or "best practices," for prostate cryoablation. These new guidelines, which included focal cryoablation, are further evidence of the growing acceptance of cryoablation within the urology physician community, Davenport noted.

About Endocare

Endocare, Inc. -- http://www.endocare.com -- is an innovative medical device company focused on the development of minimally invasive technologies for tissue and tumor ablation. Endocare has initially concentrated on developing technologies for the treatment of prostate cancer and believes that its proprietary technologies have broad applications across a number of markets, including the ablation of tumors in the kidney, lung and liver and palliative intervention (treatment of pain associated with metastases).

Statements contained in this release that are not historical facts are forward-looking statements that involve risks and uncertainties. Among the important factors which could cause actual results to differ materially from those in the forward-looking statements include, but are not limited to, those discussed in "Risk Factors" in the Company's Forms 10-K, Forms 10-Q, and other filings with the Securities and Exchange Commission. Such risk factors include, but are not limited to, uncertainty regarding the effects of the study described in this press release and any future studies and follow up data. The actual results that the Company achieves may differ materially from any forward-looking statements due to such risks and uncertainties. The Company undertakes no obligation to revise, or update publicly, any forward-looking statements for any reason.

Investor Contact: Media Contact: For Additional

Matt Clawson Len Hall Information:

Allen & Caron, Inc. Allen & Caron, Inc. Craig T. Davenport, CEO

(949) 474-4300 (949) 474-4300 Michael R. Rodriguez, CFO

matt@allencaron.com len@allencaron.com Endocare, Inc.

(949) 450-5400


'/>"/>
SOURCE Endocare, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Large Blinded Clinical Study Achieves High Accuracy for the Diagnosis of Melanoma Using In Vivo Confocal Microscopy
2. Head-to-Head Study Demonstrates Focalin(R) XR Offers Faster and Better Symptom Control than Concerta(R)1 in Early Part of ADHD Patients Day
3. Cryoablation Is Focus of 17 Clinical Studies at American Urological Association Annual Meeting
4. Leading Academic Institutions Collaborate on 800-Patient Study of Effectiveness of Cryoablation for Men With Recurrent Prostate Cancer
5. SuperGens Novel Hypomethylating Agent Highlighted at AACR Plenary Session
6. International ACTEMRA Rheumatoid Arthritis Study Highlighted in The Lancet
7. Additive Anti-Tumor Activity of NKTR-102 in Combination With Bevacizumab Highlighted in Positive Preclinical Data Presented at AACR Meeting
8. Blood Spot Technology at ZRT Highlighted in March Issue of Journal of Diabetes Science & Technology - A Convenient Alternative to Serum Testing for Health Screening
9. ATHENA Clinical Results for Dronedarone (Multaq(R)) Highlighted at the World Cardiology Congress
10. ATHENA Clinical Results with Dronedarone (Multaq(R)) Highlighted at the World Cardiology Congress
11. Marketing of Diagnostics and deCODEme(TM), Recent Progress in Drug Development to be Highlighted at deCODE R&D Event
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... INDIANAPOLIS , June 23, 2016 ... Tomorrow,s Leaders Scholarship is any indication, the future is ... online at www.diabetesscholars.org by the Diabetes Scholars ... in the way of academic and community service excellence. ... program since 2012, and continues to advocate for people ...
(Date:6/23/2016)... 2016 Revolutionary technology includes multi-speaker ... , industry leaders in advanced audiology and hearing aid ... Opn ™, the world,s first internet connected hearing aid ... devices.      (Photo: http://photos.prnewswire.com/prnh/20160622/382240 ) ... of ,world firsts,: , TwinLink™ - the ...
(Date:6/23/2016)... 23, 2016 The vast majority of dialysis ... facility.  Treatments are usually 3 times a week, with ... including travel time, equipment preparation and wait time.  This ... grueling for patients who are elderly and frail.  Many ... and rehabilitation centers for some duration of time. ...
Breaking Medicine Technology:
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... First ... United States, named Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell ... facility Medical Director of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive ...
(Date:6/25/2016)... Oklahoma City, Oklahoma (PRWEB) , ... June 25, ... ... to helping both athletes and non-athletes recover from injury. Recently, he has implemented ... for the Oklahoma City area —Johnson is one of the first doctors to ...
(Date:6/25/2016)... ... 2016 , ... Conventional wisdom preaches the benefits of moderation, whether it’s a ... the bar too high can result in disappointment, perhaps even self-loathing. However, those who ... , Research from PsychTests.com reveals that behind the tendency to set ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced traumatic events ... turn to unhealthy avenues, such as drug or alcohol abuse, as a coping mechanism. ... tools for healthy coping following a traumatic event. , Trauma sufferers tend to feel ...
(Date:6/24/2016)... ... ... a crisis. Her son James, eight, was out of control. Prone to extreme mood shifts ... upset him, he couldn’t control his emotions,” remembers Marcy. “If there was a knife ... and say he was going to kill them. If we were driving on the ...
Breaking Medicine News(10 mins):